This retrospective study from BMC Anesthesiology evaluates over 1,500 post-cesarean patients receiving patient-controlled epidural analgesia (PCEA) with either dezocine or hydromorphone. Both opioids, combined with ropivacaine, provided comparable analgesic effectiveness as measured by VAS scores, PCEA bolus demand, and rescue analgesia requirements. However, dezocine demonstrated a markedly superior safety profile, with significantly lower rates of nausea, vomiting, and pruritus—common limiting factors in obstetric opioid use.
Motor block and lower-limb numbness were comparable, suggesting that dezocine’s advantage lies primarily in fewer systemic opioid-related effects. These findings highlight dezocine as a potentially safer and more tolerable epidural opioid choice in obstetric analgesia. To explore the full dataset and clinical implications, read the complete journal article here…
